hVIVO PLC - H1 2026 Trading Update
hVIVO plc
("hVIVO", the "Company" or the "Group")
H1 2026 Trading Update
Strong commercial momentum drives more than doubling of orderbook
Highlights
• Revenue of
• Orderbook has more than doubled to
• Proposal volumes up c.45% year-on-year, supporting mid-term growth and potential further orderbook expansion in H2
• Adjusted EBITDA* for H1 2026 is expected to be negative mid-single digit (H1 2025: adjusted EBITDA of
• Cash of
· The Company expects 2026 full-year revenue to be broadly in line with expectations of high single-digit revenue growth
* Adjusted EBITDA is stated before one off exceptional items - nil in 2026 (
Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "I am pleased to report renewed commercial momentum in the first half of 2026, with one of our strongest periods of new contract sales to date. This has more than doubled our orderbook since the start of the year, providing improved revenue visibility for the remainder of 2026, 2027 and into 2028. As previously guided, revenue in 2026 is expected to be weighted to the second half with a broad mix of contracted business scheduled to commence over the coming months.
"We have made good progress executing our strategy, now operating under one brand across Consulting, Clinical Trials, Human Challenge Trials and Laboratory Services - together supporting stronger commercial activity. This diversified model will support a more balanced and resilient revenue profile and positions the Group well for sustainable future growth."
Revenue, EBITDA and cash position
The Group expects to report revenue for H1 2026 of
The Group expects to report a negative mid-single digit adjusted EBITDA for H1 2026 (H1 2025: adjusted EBITDA of
hVIVO's cash position was
Strengthened orderbook and substantial commercial momentum
The Group has demonstrated strong commercial momentum, with the orderbook increasing significantly to
The strengthened orderbook figure reflects recent contract wins and robust business development activity, with proposal volumes approximately 45% higher year-on-year to date. This is supported by positive client engagement across hVIVO's integrated, single-platform offering and providing multiple opportunities to convert further revenue through the remainder of the year. Services are increasingly contracted under one hVIVO brand, driving cross-selling opportunities and a more diversified client base.
The Group continues to see encouraging demand across infectious disease, respiratory and cardiometabolic programmes, alongside growing interest in its broader early-phase CRO and laboratory capabilities. This positive outlook was highlighted at hVIVO's recent Capital Markets Day, which included presentations from clients, investors and industry experts underlining the strength of the Company's business model as an integrated drug development partner. A recording of the Capital Markets Day is available on the Company's website.
Outlook
The Board is confident in the underlying strength of the Group's business model, underpinned by a significantly strengthened orderbook, strong visibility over contracted revenues and a growing pipeline across all four service lines. The Group's contracted client programmes remain in place, with timing shifts on certain programmes expected to result in some modest deferral of revenues previously expected in H2 2026 but now due in 2027.
Consequently, the Board's 2026 full year revenue expectation is broadly in line with existing guidance of high single-digit revenue growth, with revenue heavily weighted towards the second half of the year. This second-half weighting is expected to support positive adjusted EBITDA in H2 2026.
Together, the Group's strengthened commercial momentum, diversified full-service international clinical development platform, and robust balance sheet, position hVIVO well for sustainable mid- and long-term growth.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 |
|||
|
Yamin 'Mo' Khan, Chief Executive Officer |
|
|||
|
|
|
|||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 |
|||
|
|
|
|||
|
|
|
|||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 |
|||
|
James Steel, Dr |
|
|||
|
|
|
|||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|||
|
|
|
|||
|
|
|
|||
|
ICR Healthcare (Financial PR & IR)
|
||||
Notes to Editors
About hVIVO
hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.
The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the
With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.
· Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
· Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the
· Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in
· Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE